Asia · Markets & Finance · Pulse (Maeil Business)

Korea’s first homegrown obesity drug wins approval

Published by Pulse (Maeil Business) · South Korea 15 h ago

Hanmi Pharmaceutical’s obesity drug Epe has won regulatory approval and is set to launch by year-end, becoming South Korea’s first domestically developed glucagon-like peptide-1…

Read the full article on Pulse (Maeil Business) Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (pulse.mk.co.kr)

Also worth reading

The Straits Times Business

Jubilant FoodWorks shares in focus after Q2 revenue rises 12%, Domino’s India LFL at 4%

The Economic Times

CBI wants more time to probe NEET paper leak

Mint

Korea’s first homegrown obesity drug wins approval

Share

Also worth reading

Oil rises as Middle East supply concerns persist amid shipping attacks

Lenovo launches AI Express with Nvidia

Indian Hotels, NALCO among Ajit Mishra's 3 stock recommendations for today

Jubilant FoodWorks shares in focus after Q2 revenue rises 12%, Domino’s India LFL at 4%

CBI wants more time to probe NEET paper leak

Top stocks to watch today: TCS, Tata Steel, Reliance, Sun Pharma shares in focus on Thursday, 8 October | Full list